Reduced Leaflet Motion After Transcatheter Aortic Valve Replacement [1]
Puzzling subgroup from the GALILEO trial, which appears in the same issue of the periodical as an article that discredits the use of rivaroxaban as thromboprevention strategy :
https://www.nejm.org/doi/full/10.1056/NEJMoa1911425?query=recirc_curatedRelated_article [3],
And yet, in this particular subgroup, a subclinical benefit on leaflet mobility is being suggested! It would appear that the GALILEO will be discussed at length and in detail in the months and years to come.